Microbix Biosystems Inc. (MBXBF)
Microbix Biosystems Inc. is a life sciences company listed on OTC Markets as common stock. The company develops and commercializes biological and technology-based solutions related to human health and wellbeing, with operations in North America, Europe, and other international markets. Its product and service lines include critical biological materials and medical devices used in the global diagnostics industry, such as antigen products, test ingredients for immunoassays and diagnostic quality assessment under the QAPs brand, and viral transport medium under the DxTM brand for collecting patient samples and supporting pathogen testing. Microbix also markets Kinlytic, a biologic thrombolytic drug used in the treatment of blood clots, and provides customer vial filling services. The company was founded in 1988 and is headquartered in Mississauga, Canada.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-MBXB.F
|
$0.17
|
-20.1% Downside
|
Overvalued
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 13, 2026
|
-7.2x
|
1.6x
|
2.8x
|
29.394 M
|
28.745 M
|
14.1%
|
83.4%
|
4.5
|
—
|
96.5%
|
